BACKGROUND: The neuroendocrine marker, chromogranin A (CgA) increases during medium- or long-term proton-pump inhibitor (PPI) treatment. AIMS: To analyze the effect of ultra-short-term and diverse dose of PPI therapy on serum CgA and gastrin levels and evaluate the effect of PPI treatment cessation. PATIENTS AND METHODS: Fasting serum CgA and gastrin were determined in newly diagnosed gastroesophageal reflux disease (GERD) patients (n = 54) treated with diverse doses of PPI during a 28-day period, in patients treated with PPIs for at least 6 months (n = 42), and in subjects where PPI treatment could be stopped (n = 11). RESULTS: A significant stepwise increase of CgA levels was observed after 5 days during the 28-day period treatment with all PPI doses. Gastrin increased significantly also in the standard and high-dose PPI subgroups. The most prominent increase of CgA was observed in the high-dose PPI subgroup. Serum CgA and gastrin were markedly elevated after 6 months of PPI treatment, and decreased significantly after 5 days of PPI discontinuation. CONCLUSIONS: Serum CgA increases significantly even after ultra-short-term (5 days) PPI therapy. After long-term treatment, 5-day cessation of PPI therapy is sufficient to decrease significantly both CgA and gastrin levels.
BACKGROUND: The neuroendocrine marker, chromogranin A (CgA) increases during medium- or long-term proton-pump inhibitor (PPI) treatment. AIMS: To analyze the effect of ultra-short-term and diverse dose of PPI therapy on serum CgA and gastrin levels and evaluate the effect of PPI treatment cessation. PATIENTS AND METHODS: Fasting serum CgA and gastrin were determined in newly diagnosed gastroesophageal reflux disease (GERD) patients (n = 54) treated with diverse doses of PPI during a 28-day period, in patients treated with PPIs for at least 6 months (n = 42), and in subjects where PPI treatment could be stopped (n = 11). RESULTS: A significant stepwise increase of CgA levels was observed after 5 days during the 28-day period treatment with all PPI doses. Gastrin increased significantly also in the standard and high-dose PPI subgroups. The most prominent increase of CgA was observed in the high-dose PPI subgroup. Serum CgA and gastrin were markedly elevated after 6 months of PPI treatment, and decreased significantly after 5 days of PPI discontinuation. CONCLUSIONS: Serum CgA increases significantly even after ultra-short-term (5 days) PPI therapy. After long-term treatment, 5-day cessation of PPI therapy is sufficient to decrease significantly both CgA and gastrin levels.
Authors: Malcolm Boyce; Frans van den Berg; Toni Mitchell; Kate Darwin; Steve Warrington Journal: Eur J Clin Pharmacol Date: 2016-10-29 Impact factor: 2.953
Authors: Alexander V Fisher; Alexandra G Lopez-Aguiar; Victoria R Rendell; Courtney Pokrzywa; Flavio G Rocha; Zaheer S Kanji; George A Poultsides; Eleftherios A Makris; Mary E Dillhoff; Eliza W Beal; Ryan C Fields; Roheena Z Panni; Kamran Idrees; Paula Marincola Smith; Clifford S Cho; Megan V Beems; Shishir K Maithel; Emily R Winslow; Daniel E Abbott; Sharon M Weber Journal: J Gastrointest Surg Date: 2019-01-18 Impact factor: 3.452
Authors: Somer Matar; Anna Malczewska; Kjell Oberg; Lisa Bodei; Harry Aslanian; Anna Lewczuk-Myślicka; Pier Luigi Filosso; Alejandro L Suarez; Agnieszka Kolasińska-Ćwikła; Matteo Roffinella; Beata Kos-Kudła; Jarosław B Ćwikła; Ignat A Drozdov; Mark Kidd; Irvin M Modlin Journal: Neuroendocrinology Date: 2019-04-16 Impact factor: 4.914
Authors: Hólmfridur Helgadóttir; Sigrún H Lund; Sveinbjörn Gizurarson; David C Metz; Einar S Björnsson Journal: J Clin Gastroenterol Date: 2020-03 Impact factor: 3.062
Authors: Eugen Melcescu; Reed B Hogan; Keith Brown; Stewart A Boyd; Thomas L Abell; Christian A Koch Journal: Exp Mol Pathol Date: 2012-10-05 Impact factor: 3.362